Business

FDA approves Eli Lilly Alzheimer’s drug, expanding treatment options in the U.S.

It’s a long-awaited win for Eli Lilly after donanemab faced several delays in its path to the market, including an initial rejection from the FDA last year.

Previous post Tens of millions of people are watching videos of home buyers sitting in empty houses
Next post I’m 73 and have $930,000 in my IRA. Should I wait for the market to go down before I do a Roth conversion?

More Stories